ABBV - AbbVie Inc.

NYSE - Nasdaq Real Time Price. Currency in USD

93.19

-0.30 (-0.32%)

As of 3:57PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	93.49
Open	93.47
Bid	93.12 x 800
Ask	93.05 x 900
Day's Range	92.10 - 94.36
52 Week Range	69.38 - 125.86
Volume	4,576,214
Avg. Volume	8,800,341

Market Cap	141.095B
Beta	1.63
PE Ratio (TTM)	23.43
EPS (TTM)	3.98
Earnings Date	Jul 26, 2018 - Jul 30, 2018
Forward Dividend & Yield	3.84 (4.11%)
Ex-Dividend Date	2018-07-12
1y Target Est	113.62

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswire7 hours ago
IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
- The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including ...
Zacks7 hours ago
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric
PR Newswire9 hours ago
AbbVie and Calibr announce collaboration for next generation T-cell therapies
NORTH CHICAGO, Ill. and LA JOLLA, Calif., June 25, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors. This collaboration broadens AbbVie's oncology research to access advanced precision medicine technology to expand the development of potentially life-changing treatments for patients with cancer.
Motley Foolyesterday
Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines
These drugmakers arguably have the strongest pipelines. But are they all great stocks to buy?
Simply Wall St.3 days ago
Is AbbVie Inc (NYSE:ABBV) A Buy At Its Current PE Ratio?
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning the link between AbbVie Inc (NYSE:ABBV)’s fundamentals and stockRead More...
Zacks3 days ago
Top Research Reports for Procter & Gamble, AbbVie & IBM
Top Research Reports for Procter & Gamble, AbbVie & IBM
Benzinga4 days ago
Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 20) Agios Pharmaceuticals Inc (NASDAQ: AGIO )(announced initiation ...
ACCESSWIRE4 days ago
Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities
North Chicago, Illinois-based AbbVie Inc.'s stock finished Wednesday's session 0.24% higher at $98.25 with a total trading volume of 4.68 million shares. The Company's shares have advanced 37.95% over the past year.
Motley Fool5 days ago
5 Experimental New Drugs That Could Be Worth $47 Billion
Optimism for these research and development projects is higher than all the rest.
Motley Fool5 days ago
Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
J&J's dividend is good. But these are even better.
PR Newswire6 days ago
8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities"
The Civic 50 recognizes AbbVie as one of the most community-minded companies in the U.S. - For the fifth consecutive year, AbbVie teams up with leading nonprofits to enhance education and opportunities for the underserved. - The AbbVie Foundation has impacted nearly 19 million lives around the world since it was established in 2014.
ACCESSWIRE6 days ago
Wired News – AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress
LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on AbbVie Inc. (NYSE: ABBV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ABBV as the Company’s latest news hit the wire. On June 15, 2018, the Company announced that it has presented investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase-3 MURANO trial, assessing venetoclax in combination with rituximab (VenR) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) during the 23rd European Hematology Association (EHA) Annual Congress, Stockholm, held on June 16, 2018.
Motley Fool6 days ago
3 Great Reasons to Buy Gilead Sciences
This down-and-out biotech stock could be ready to rebound soon.
Zacks7 days ago
Bristol-Myers Posts Data on Empliciti, China Approves Opdivo
Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.
Reuters7 days ago
How U.S. tax reform rewards companies that shift profit to tax havens
The new tax bill cuts the overall corporate tax rate to 21 percent, and allows income from overseas to be taxed at about half that rate – to as low as 10 percent. AbbVie Inc. (ABBV.N) is a case in point. Its Chief Executive Richard Gonzalez told investors earlier this year that because of the change to a territorial system, whereby only profits reported by domestic subsidiaries face U.S. tax, the U.S. drugmaker expects its tax rate to fall to 9 percent this year from around 22 percent in recent years.
ACCESSWIRE7 days ago
Today's Research Reports on Trending Tickers: Canopy Growth and AbbVie
NEW YORK, NY / ACCESSWIRE / June 18, 2018 / U.S. market plunged on Friday, but well-off session lows as investors appeared to look at previous signs of escalating trade tension between Washington and Beijing. ...
Reuters7 days ago
How U.S. tax reform rewards companies that shift profit to tax havens
The new tax bill cuts the overall corporate tax rate to 21 percent, and allows income from overseas to be taxed at about half that rate – to as low as 10 percent. AbbVie Inc. is a case in point. Its Chief Executive Richard Gonzalez told investors earlier this year that because of the change to a territorial system, whereby only profits reported by domestic subsidiaries face U.S. tax, the U.S. drugmaker expects its tax rate to fall to 9 percent this year from around 22 percent in recent years.
Motley Fool8 days ago
Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
Zacks10 days ago
Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Motley Fool10 days ago
3 High-Yield Stocks at Rock-Bottom Prices
Looking for value and income? These three companies have you covered.
Motley Fool10 days ago
Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Which big pharma stock wins in a head-to-head comparison?
GlobeNewswire10 days ago
Analysis: Positioning to Benefit within Canopy Growth, Aurora Cannabis, CannTrust, AbbVie, Cronos Group, and Scotts Miracle-Gro — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Canopy ...
PR Newswire11 days ago
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
- 83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months ...
PR Newswire11 days ago
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , June 14, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Aug. 15, 2018 ...
Yahoo Finance Video10 days ago
MARKETS: Here's why stocks are dropping right now
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.